Len Schleifer and George Yancopoulos once again land in the top ranks of the highest paid execs in biopharma
Len Schleifer and George Yancopoulos clearly enjoy the compensation course they’ve set for themselves over the last few years. This year Regeneron’s CEO and research czar — chief doesn’t cut it anymore — grabbed packages of stock awards $REGN and options that pushed the total up to $26.5 million and $25.4 million, respectively.
The Regeneron co-founders are among the most aggressive biotech players in the industry, and they’ve paid themselves among the highest compensation rates in the industry for years now.
Schleifer’s pay puts him in the top 5 for the year so far, far ahead of most of the Big Pharma leaders, as you can see in the chart below. And Yancopoulos always is at the top of the charts for any research executive in the business.
These two are not shy. Schleifer will gladly strike a contrarian pose on drug prices or any other topic he chooses. And they don’t mind claiming what they feel is right, which applies to just about everything.
Several years ago I was looking for a place to sit in the Hilton lobby near Union Square and had my hand on the back seat of an open chair only to have Schleifer turn around and plant his hand on it.
“That’s ours,” he said, looking me squarely and unapologetically in the eyes. Of course, I let him have it.
“It’s us against the world,” Yancopoulos told me during January’s JP Morgan event, lambasting the PD-1/L1 leaders for marketing often inadequate therapies while leaving some gaping holes in the checkpoint market for a latecomer like Regeneron to exploit.
Regeneron has built a blockbuster rep for making antibodies better than most. The jobs have paid well. The average pay at the biotech is $134,115 a year, a ratio of 198 to 1 compared to what Schleifer made.
Image: Len Schleifer and George Yancopoulos. NYSCI via VIMEO